<DOC>
	<DOCNO>NCT00885872</DOCNO>
	<brief_summary>This study evaluate effect rosuvastatin 10-20 mg carotid atherosclerosis progression Chinese patient evaluate change percentage volume lipid rich necrotic core ( LRNC ) use high-resolution magnetic resonance imaging ( MRI ) 24-months treatment .</brief_summary>
	<brief_title>Rosuvastatin Evaluation Atherosclerotic Chinese Patients ( REACH )</brief_title>
	<detailed_description>The primary objective study evaluate effect rosuvastatin 10-20 mg carotid atherosclerosis progression Chinese patient evaluate change percentage volume lipid rich necrotic core ( LRNC ) use high-resolution magnetic resonance imaging ( MRI ) 24-months treatment .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Male female patient 18 75 year age , inclusive . 2 . LDLC concentration ≥ 100mg/dl ( 2.6mmol/L ) , less 250mg/dl ( 6.5mmol/L ) ; TG ≤ 353mg/dl ( 4.0mmol/L ) . 3 . New patient regard statin therapy . 4 . 16 % 69 % carotid artery stenosis duplex ultrasound . At least one carotid plaques detectable either right leave side carotid artery 2.4 cm proximal 2.4 cm distal bifurcation . Plaque must 3 mm thick calcification present less 50 % plaque area . The plaque must LRNC intact fibrous cap detect contrastenhanced MRI ( CE MRI ) . 5 . Female patient must agree use effective form birth control throughout 2year study treatment period . They must either document postmenopausal , physically surgically incapable bearing child , use barrier contraceptive method . In addition use contraception , woman childbearing potential must also negative serum pregnancy test Screening . 6 . The patient willing enrol remain low cholesterol dietary ( refer Chinese Guideline Treatment Dyslipidemia Adult ) study duration . 7 . The patient must able comply schedule visit , treatment plan laboratory test . 8 . The patient must provide write voluntary inform consent participate study . 1 . The patient liver function test &gt; 1.5 time upper limit normal , serum creatinine &gt; 2.0 mg/dL , GFR &lt; 30 ml/min abnormal laboratory value deem clinically significant investigator . 2 . The patient severe heart disease , include NYHA IIIIV , uncontrolled arrhythmia acute coronary syndrome . The patient coronary artery bypass graft ( CABG ) , percutaneous coronary intervention ( PCI ) , carotid endarterectomy ( CEA ) , carotid artery stent , low extremity revascularization/amputation . The patient unstable angina myocardial infarct within 3 month enrolment . 3 . The patient plan surgical/endovascular intervention carotid , coronary and/or peripheral arterial disease course study . 4 . The patient critical limb ischemia , evidence ischemic rest pain , ulceration , gangrene . 5 . The patient treat evaluate diagnosed tuberculosis . The patient chest xray obtain within last month show sign consistent possible tuberculosis . 6 . The patient history malignant neoplasm within previous 5 year ( exception : curable nonmelanoma skin malignancy ) . 7 . The patient know immunodeficient state ( e.g. , human immunodeficiency virus ) treat immunosuppressive drug include cyclosporine . 8 . The patient take medicine follow : Hormonal therapy Cyclosporine Other lipid lower agent : fish oil , garlic essential oil etc . 9 . The patient suffer deep vein thrombosis within previous 3 month . 10 . The patient suffer brain haemorrhage study . 11 . The patient history recent alcohol abuse , drug abuse significant mental illness . 12 . The patient condition would prevent patient give voluntary informed consent . 13 . The patient inability tolerate oral medication administration . 14 . The patient know suspect allergy study medication ( ) class study medication administer . 15 . The patient know suspected allergy MRI contrast agent ( e.g. , gadolinium ) . 16 . The patient enrol plan enroll another clinical drug device/interventional trial study . 17 . The patient clinically significant medical condition , opinion Investigator , could impact patient 's ability successfully complete trial . 18 . The patient history myopathy . 19 . The patient history epilepsy/seizures . 20 . The patient thyroid stimulate hormone ( TSH ) &gt; 1.5xULN . 21 . The patient LDL cholesterol &gt; 250mg/dL total cholesterol &gt; 309 mg/dL familial hypercholesterolemia . 22 . The patient uncontrolled hypertension , SBP &gt; 160 mmHg / DBP &gt; 100 mmHg . 23 . The patient uncontrolled hyperglycemia HbA1c &gt; 9 % diagnosed DM recently ( within 1 month enrolment ) 24 . BMI ≥ 30 kg/m2 25 . The patient pacemaker metallic foreign body .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>